Basic information Safety Supplier Related

RAF709

Basic information Safety Supplier Related

RAF709 Basic information

Product Name:
RAF709
Synonyms:
  • CS-2505
  • RAF-709;RAF 709
  • RAF709
  • Benzamide, N-[2-methyl-5'-(4-morpholinyl)-6'-[(tetrahydro-2H-pyran-4-yl)oxy][3,3'-bipyridin]-5-yl]-3-(trifluoromethyl)-
  • N-[2-Methyl-5'-(4-morpholinyl)-6'-[(tetrahydro-2H-pyran-4-yl)oxy][3,3'-bipyridin]-5-yl]-3-(trifluoromethyl)benzamide
  • Inhibitor,inhibit,Raf,Raf kinases,RAF709,RAF-709,RAF 709
  • N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide
  • RAF709, 10 mM in DMSO
CAS:
1628838-42-5
MF:
C28H29F3N4O4
MW:
542.55
Mol File:
1628838-42-5.mol
More
Less

RAF709 Chemical Properties

Boiling point:
622.7±55.0 °C(Predicted)
Density 
1.321±0.06 g/cm3(Predicted)
storage temp. 
Store at -20°C
solubility 
DMSO:100.0(Max Conc. mg/mL);184.31(Max Conc. mM)
DMSO:PBS (pH 7.2) (1:2):0.33(Max Conc. mg/mL);0.61(Max Conc. mM)
DMF:30.0(Max Conc. mg/mL);55.29(Max Conc. mM)
Ethanol:100.0(Max Conc. mg/mL);184.31(Max Conc. mM)
form 
A crystalline solid
pka
11.87±0.70(Predicted)
color 
White to off-white
More
Less

Safety Information

HS Code 
2934999090
More
Less

RAF709 Usage And Synthesis

Description

RAF709 is a potent inhibitor of B-RAF and C-RAF (IC50s = 0.4 and 0.5 nM, respectively). It is selective for RAF kinases exhibiting >99% inhibition of only B-RAF, B-RAFV600E, and C-RAF in a panel of 456 kinases. However, DDR1, DDR2, FRK, and PDGFRβ are also inhibited by >80% at a concentration of 1 μM. RAF709 inhibits phosphorylation of MEK and ERK (EC50s = 0.02 and 0.1 μM, respectively) with minimal paradoxical activation, stabilizes BRAF-CRAF dimers (EC50 = 0.8 μM), and reduces proliferation of Calu-6 RAS mutant cells (EC50 = 0.95 μM). In a Calu-6 mouse non-small cell lung cancer (NSCLC) xenograft model, RAF709 (10-200 mg/kg) reduces ERK phosphorylation and decreases tumor volume in a dose-dependent manner without affecting total body weight.

Uses

RAF709 is a potent, selective, and efficacious RAF inhibitor with IC50s of 0.4 nM and 0.5 nM for BRAF and CRAF, respectively[1]. Antitumor efficacy[1].

in vivo

RAF709 proves to be soluble, kinase selective, and efficacious in a KRAS mutant xenograft model. RAF709 shows dose-proportional increases in plasma exposure and a corresponding dosedependent inhibition of pERK in Calu-6 tumors. Treatment with RAF709 results in dose-dependent antitumor activity with 10 mg/kg being subefficacious (%T/C=92%), 30 mg/kg results in measurable antitumor activity (%T/C=46%), and 200 mg/kg results in mean tumor regression of 92%, while the same high dose is not efficacious in the PC3, KRAS WT model[1].

IC 50

CRAF: 0.5 nM (IC50); Braf: 0.4 nM (IC50)

References

[1] Nishiguchi GA, et al. Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers. J Med Chem. 2017 Jun 22;60(12):4869-4881. DOI:10.1021/acs.jmedchem.6b01862

RAF709Supplier

Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
AdooQ Bioscience CHINA
Tel
025-58849295 18951903616;
Email
info@adooq.cn
Shanghai Lollane Biological Technology Co.,Ltd.
Tel
021-52996696,15000506266 15000506266
Shanghaizehan biopharma technology co., Ltd.
Tel
021-61350663 13052117465
Email
sales@zehanbiopharma.com
Shanghai EFE Biological Technology Co., Ltd.
Tel
021-65675885 18964387627
Email
info@efebio.com
More
Less

RAF709(1628838-42-5)Related Product Information